Eris Lifesciences reported Q2 2025 revenue of INR 792 crores, missing forecasts, but achieved a robust 39% year-over-year increase in profit after tax to INR 134 crores, though its stock dipped 1.23%. The company is strategically expanding its insulin market presence, including adding Aspart to its Biocon partnership, and is highly optimistic about the GLP-1 market, projecting a potential $1 billion opportunity in India. Eris also secured a substantial European CDMO order book of INR 700-800 crores and plans to front-load INR 380-400 crores in CapEx to capitalize on these growth avenues, while targeting a net debt-to-EBITDA ratio below 1.5x by December 2026.
Eris Lifesciences reported Q2 2025 consolidated revenue of INR 792 crores, falling short of the INR 806 crores forecast, yet delivered a strong 39% year-over-year increase in profit after tax (PAT) to INR 134 crores. Despite these positive financial results, the company's stock experienced a 1.23% decline, suggesting market focus on the revenue miss. The company is strategically expanding its high-growth segments, notably in the insulin market through an enhanced Biocon partnership and an optimistic outlook on the GLP-1 market, projecting a potential $1 billion opportunity in India. Eris also secured a substantial INR 700-800 crore order book for its European CDMO business, anticipating significant international revenue growth from FY2027. Financially, Eris has significantly improved its net debt-to-EBITDA ratio from 4x to 2x in 18 months, targeting below 1.5x by December 2026. Management plans to front-load INR 380-400 crores in CapEx over the next three quarters, funded by internal accruals, to support these growth initiatives and aims for 50% growth ahead of the market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
